Wednesday’s Daily Piece: Dapagliflozin Now Has Cardiovascular Indication Beyond Diabetes

How exciting! Dapagliflozin (Farxiga) initially approved for treatment of type 2 diabetes now has an indication beyond its use in diabetes. FDA has given dapagliflozin an indication for heart failure with reduced ejection fraction (HFrEF) to reduce risk of cardiovascular death and hospitalization for heart failure. Please click below to read more details.

FARXIGA® (dapagliflozin) | Type 2 Diabetes Medication for Adults
How Many Drugs has FDA Approved in its Entire History? New Paper ...
This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#heart #failure #indication #Farxiga #FDA

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

Leave a Reply

Your email address will not be published. Required fields are marked *